RUA Life Sciences (RUA)

Sector:

Health Care

Index:

FTSE AIM All-Share

11.24p
   
  • Change Today:
    -0.27p
  • 52 Week High: 46.50
  • 52 Week Low: 8.75
  • Currency: UK Pounds
  • Shares Issued: 62.06m
  • Volume: 136,233
  • Market Cap: £6.97m
  • RiskGrade: 290

RUA Life Sciences tumbles as losses look set to widen

By Josh White

Date: Friday 27 May 2022

LONDON (ShareCast) - (Sharecast News) - RUA Life Sciences reported increased sales growth in a full-year trading update on Friday, amid recovery from Covid-19 disruption and advances in its business processes and management to minimise the risk of a further delay to the regulatory approval of RUA Vascular's graft range.
The AIM-traded firm said it expected to have generated consolidated unaudited revenues of £1.63m in the 12 months ended 31 March, up 6% year-on-year.

Unaudited research and development spend was expected to total £0.89m - an increase of £0.35m over the preceding year, demonstrating continued investment in this area.

Overall, its loss before tax was expected to have widened to £2.36m from £1.59m, resulting from a combination of increased research and development activities and further investment in the infrastructure to support future growth.

The company's balance sheet was expected to show a cash balance at the end of the year of £2.96m, down from £6.29m, having invested more than £0.5m in capital equipment during the year.

RUA said the equipment included heart valve testing equipment, graft manufacturing scale-up equipment, and a new factory unit to accommodate the high-output cleanroom facility to support scale-up manufacturing of RUA Vascular's graft range and associated support functions.

The new facility was set to be commissioned in 2023.

"We continue on our journey to develop the scale and expertise required of a fully-fledged medical device manufacturer, that will allow us to deliver on our ambitious plans," said group managing director Caroline Stretton.

"Our strengthened business strategy will maximise contribution from new product pipelines and positions the group well for sustainable and profitable growth."

At 1026 BST, shares in RUA Life Sciences were down 14.19% at 39.9p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

RUA Market Data

Currency UK Pounds
Share Price 11.24p
Change Today -0.27p
% Change -2.30 %
52 Week High 46.50
52 Week Low 8.75
Volume 136,233
Shares Issued 62.06m
Market Cap £6.97m
RiskGrade 290

RUA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
85.79% below the market average85.79% below the market average85.79% below the market average85.79% below the market average85.79% below the market average
51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average
Income Not Available
Growth
37.54% above the market average37.54% above the market average37.54% above the market average37.54% above the market average37.54% above the market average
61.11% above the sector average61.11% above the sector average61.11% above the sector average61.11% above the sector average61.11% above the sector average

RUA Dividends

No dividends found

Trades for 18-Apr-2024

Time Volume / Share Price
08:16 80,000 @ 11.17p
08:09 6,233 @ 11.25p
08:04 50,000 @ 11.72p

RUA Key Personnel

Chair William D Brown
CFO Lachlan Smith

Top of Page